How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

113,131 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. (PubMed)

Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Concentrations of soluble (s)ST2 predict prognosis in heart failure. We recently found changing doses of β-blocker (BB) may affect sST2 concentrations. It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96 (...) sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events). Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard. Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event. Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02). Similar

Full Text available with Trip Pro

2013 Circulation. Heart failure

162. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2

, Poppe B. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 243. 2015 Authors' objectives This guideline treats the Birt-Hogg-Dubé syndrome, the familial atypical multiple mole melanoma syndrome and neurofibromatosis 1&2. These syndromes only have in common that dermatological manifestations are involved, but implications, risks (...) Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2 Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Robays J, Stordeur S, Hulstaert F

2015 Health Technology Assessment (HTA) Database.

163. Eliglustat for treating type 1 Gaucher disease

project team 43 Evaluation committee members 43 NICE project team 43 Eliglustat for treating type 1 Gaucher disease (HST5) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 441 1 Recommendations Recommendations 1.1 Eliglustat is recommended within its marketing authorisation for treating type 1 Gaucher disease, that is, for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive (...) Eliglustat for treating type 1 Gaucher disease Eliglustat for treating type 1 Gaucher Eliglustat for treating type 1 Gaucher disease disease Highly specialised technologies guidance Published: 28 June 2017 nice.org.uk/guidance/hst5 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful

2017 National Institute for Health and Clinical Excellence - Highly specialised technology

164. “Treat me with respect”. What happens before, during and after coercion?

Treat me with respect”. What happens before, during and after coercion? “Treat me with respect”. What happens before, during & after coercion? Search National Elf Service Search National Elf Service » » » » » “Treat me with respect”. What happens before, during and after coercion? Nov 17 2017 Posted by Incidents involving violence and aggression are a frequent occurrence in adult mental health inpatient settings. They are managed by use of restrictive interventions (coercive practices (...) the therapeutic relationship between the patient and staff. Physical discomfort This included the effects and side effects of medication, as well as the physical and psychological effects of restraint, or seclusion. Other consequences The published literature suggested that longer term psychological outcomes resulted in subsequent trauma and potential delays to recovery. Psychiatric patients associate the use of coercive interventions with strong negative perceptions and wish to be treated with respect

2017 The Mental Elf

165. Asfotase alfa for treating paediatric-onset hypophosphatasia

are likely to spend many days in hospital with their child, which reduces time with other family members and results in time away from work (or stopping work entirely). The daily lives of carers are affected because of the child's seizures and the need to regularly monitor oxygen levels. Patient experts highlighted that because of the limited numbers of centres treating hypophosphatasia in England, long journeys for appointments or inpatient stays may be needed regularly. This sometimes leads to families (...) Conclusion 43 Summary of evaluation committee's key conclusions 44 6 Implementation 52 7 Evaluation committee members and NICE project team 53 Evaluation committee members 53 NICE project team 53 Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 541 1 Recommendations Recommendations 1.1 Asfotase alfa is recommended as an option for treating paediatric

2017 National Institute for Health and Clinical Excellence - Highly specialised technology

166. Migalastat for treating Fabry disease

members 31 NICE project team 31 Migalastat for treating Fabry disease (HST4) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 311 1 Recommendations Recommendations 1.1 Migalastat is recommended, within its marketing authorisation, as an option for treating Fabry disease in people over 16 years of age with an amenable mutation, only if migalastat is provided with the discount agreed in the patient access scheme (...) is taken on by family members. Many people with Fabry disease have had psychological difficulties coming to terms with a lifelong progressive disorder, particularly before the introduction of enzyme replacement therapy (ERT) in 2001. ERT has a number of benefits but it also has limitations. The infusion dosage schedule of every 2 weeks means that people with Fabry disease cannot plan trips away from home. ERT must be kept refrigerated and there are risks of developing an infusion- related infection

2017 National Institute for Health and Clinical Excellence - Highly specialised technology

167. Evidence-based guidelines for treating bipolar disorder

be promoted (II). Identify and try to modify habitual, very irregular patterns of activity, which are common in patients with bipolar disorder: con- sider using diaries or apps to self-monitor mood or activities (III). Since alcohol and drug use are associated with a poor outcome, they require assessment, appropriate advice and treatment (S). Help the patient, family members, and significant others rec- ognize emerging symptoms of manic or depressive episodes so that they may know when to request early (...) intervention (S).502 Journal of Psychopharmacology 30(6) A consistent long-term flexible alliance between the patient, the patient’s family and key members of a psychiatric team, including an effective, appropriately trained psychiatrist, is the ideal arrangement for outpatient care. The input of family mem- bers may also enhance the patient’s treatment adherence (S). (e) Evaluate and manage functional impairments. Full functional recovery seldom occurs within 12 weeks following the remission of mood

2016 British Association for Psychopharmacology

168. Evidence-based Guidelines for Treating Bipolar Disorder

be promoted (II). Identify and try to modify habitual, very irregular patterns of activity, which are common in patients with bipolar disorder: con- sider using diaries or apps to self-monitor mood or activities (III). Since alcohol and drug use are associated with a poor outcome, they require assessment, appropriate advice and treatment (S). Help the patient, family members, and significant others rec- ognize emerging symptoms of manic or depressive episodes so that they may know when to request early (...) intervention (S).502 Journal of Psychopharmacology 30(6) A consistent long-term flexible alliance between the patient, the patient’s family and key members of a psychiatric team, including an effective, appropriately trained psychiatrist, is the ideal arrangement for outpatient care. The input of family mem- bers may also enhance the patient’s treatment adherence (S). (e) Evaluate and manage functional impairments. Full functional recovery seldom occurs within 12 weeks following the remission of mood

2016 British Association for Psychopharmacology

169. Cladribine tablets for treating relapsing?remitting multiple sclerosis

-effectiveness results and conclusion 18 4 Implementation 20 5 Appraisal committee members and NICE project team 21 Appraisal committee members 21 NICE project team 21 Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 221 1 Recommendations Recommendations 1.1 Cladribine tablets are recommended as an option for treating highly active multiple (...) Cladribine tablets for treating relapsing?remitting multiple sclerosis Cladribine tablets for treating Cladribine tablets for treating relapsing–remitting multiple sclerosis relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

170. Ibrutinib for treating Waldenstrom?s macroglobulinaemia

discussion 7 Clinical effectiveness 7 Cost effectiveness 11 Potential equality issues 15 Pharmaceutical Price Regulation Scheme (PPRS) 2014 15 Summary of appraisal committee's key conclusions 16 5 Implementation 22 6 Recommendation for data collection 23 7 Appraisal committee members and NICE project team 24 Appraisal committee members 24 NICE project team 24 Ibrutinib for treating Waldenstrom’s macroglobulinaemia (TA491) © NICE 2018. All rights reserved. Subject to Notice of rights (https (...) Ibrutinib for treating Waldenstrom?s macroglobulinaemia Ibrutinib for treating W Ibrutinib for treating Waldenstrom aldenstrom’s ’s macroglobulinaemia macroglobulinaemia T echnology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta491 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

171. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours

Implementation 16 5 Appraisal committee members and NICE project team 17 Appraisal committee members 17 NICE project team 17 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 181 1 Recommendations Recommendations 1.1 Regorafenib is recommended as an option for treating unresectable or metastatic gastrointestinal stromal (...) and that these are managed on an individual basis to achieve a balance between the minimal effective dose and side effects that can be tolerated. The patient experts explained that regorafenib allows people to Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 18remain actively engaged in work and family life, while reducing anxiety

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

172. Nivolumab for previously treated non-squamous non-small-cell lung cancer

Recommendations 4 2 The technology 5 3 Evidence 6 4 Committee discussion 7 Nature of the condition 7 Clinical management of the condition 7 Comparators 8 Clinical effectiveness 8 Cost effectiveness 11 End-of-life considerations 20 Innovation 21 Cancer Drugs Fund 21 Overall conclusions 24 Summary of appraisal committee's key conclusions 25 5 Implementation 32 6 Appraisal committee members and NICE project team 33 Appraisal committee members 33 NICE project team 33 Nivolumab for previously treated non-squamous (...) Nivolumab for previously treated non-squamous non-small-cell lung cancer Niv Nivolumab for pre olumab for previously treated non- viously treated non- squamous non-small-cell lung cancer squamous non-small-cell lung cancer T echnology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta484 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

173. Venetoclax for treating chronic lymphocytic leukaemia

Symptoms and management of CLL 7 Clinical effectiveness 9 Indirect comparison with best supportive care 12 Cost effectiveness 13 Cancer Drugs Fund considerations 20 Summary of appraisal committee's key conclusions 22 5 Implementation 30 6 Recommendations for data collection 31 7 Appraisal committee members and NICE project team 32 Appraisal committee members 32 NICE project team 32 Venetoclax for treating chronic lymphocytic leukaemia (TA487) © NICE 2018. All rights reserved. Subject to Notice (...) Venetoclax for treating chronic lymphocytic leukaemia V Venetoclax for treating chronic enetoclax for treating chronic lymphocytic leukaemia lymphocytic leukaemia T echnology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

174. Bisphosphonates for treating osteoporosis

committee members and NICE project team 24 Appraisal committee members 24 NICE project team 24 Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 25This guidance partially replaces TA160 and TA161. 1 1 Recommendations Recommendations The purpose of this technology appraisal was to establish at what level of absolute fracture risk bisphosphonates are cost-effective (...) a decision support aid to help support this discussion. If the person wishes to try a bisphosphonate, they should be able to start treatment with the least expensive formulation, with no other local formulary or funding restrictions. Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 23 of 255 5 Appr Appraisal committee members and NICE project team aisal committee members

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

175. Cabozantinib for previously treated advanced renal cell carcinoma

Evidence 6 4 Committee discussion 7 Treatment pathway 7 Population and comparators 8 Clinical effectiveness 9 Cost effectiveness 11 End-of-life considerations 17 Results of cost-effectiveness analyses 17 Innovation 19 Pharmaceutical Price Regulation Scheme (PPRS) 2014 19 Summary of appraisal committee's key conclusions 19 5 Implementation 25 6 Appraisal committee members and NICE project team 26 Appraisal committee members 26 NICE project team 26 Cabozantinib for previously treated advanced renal cell (...) curves for all the treatments. However, the committee agreed that it was a more flexible family, which improved the curve fits to the Kaplan–Meier Cabozantinib for previously treated advanced renal cell carcinoma (TA463) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 27data on overall and progression-free survival for all treatments in the network compared with the original parametric modelling using the log

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

176. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane

committee members and NICE project team 30 Appraisal committee members 30 NICE project team 30 Update information 32 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 32This guidance replaces TA371. 1 1 Recommendations Recommendations 1.1 Trastuzumab emtansine is recommended, within its marketing (...) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane T T r rastuzumab emtansine for treating astuzumab emtansine for treating HER2-positiv HER2-positive advanced breast cancer e advanced breast cancer after tr after trastuzumab and a taxane astuzumab and a taxane T echnology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta458 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

177. Adalimumab and dexamethasone for treating non-infectious uveitis

Evidence 7 4 Committee discussion 8 Clinical need and management of non-infectious uveitis 8 Clinical effectiveness 9 Cost effectiveness 12 Summary of appraisal committee's key conclusions 19 5 Implementation 27 6 Appraisal committee members and NICE project team 28 Appraisal committee members 28 NICE project team 28 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice (...) Adalimumab and dexamethasone for treating non-infectious uveitis Adalimumab and de Adalimumab and dexamethasone for xamethasone for treating non-infectious uv treating non-infectious uveitis eitis T echnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta460 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

178. Carfilzomib for previously treated multiple myeloma

problem and treatment pathway 8 Clinical effectiveness 11 Cost effectiveness 14 Most plausible incremental cost-effectiveness ratio 17 End-of-life considerations 19 Conclusion 19 Summary of appraisal committee's key conclusions 20 5 Implementation 27 6 Appraisal committee members and NICE project team 28 Appraisal committee members 28 NICE project team 28 Carfilzomib for previously treated multiple myeloma (TA457) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk (...) treated multiple myeloma (TA457) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 27 of 296 6 Appr Appraisal committee members and NICE project team aisal committee members and NICE project team Appraisal committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

179. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma

project team 19 Appraisal committee members 19 NICE project team 19 Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 201 1 Recommendations Recommendations 1.1 Olaratumab, in combination with doxorubicin, is recommended for use within the Cancer Drugs Fund as an option for advanced soft tissue sarcoma in adults, only (...) in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 18 of 206 6 Appr Appraisal committee members and NICE project team aisal committee members and NICE project team Appraisal committee members The technology appraisal committees are standing advisory committees of NICE. This topic was considered by members of the existing standing committees who

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

180. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia

committee members 21 NICE project team 21 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 221 1 Recommendations Recommendations 1.1 Blinatumomab is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute (...) Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Blinatumomab for pre Blinatumomab for previously treated viously treated Philadelphia-chromosome-negativ Philadelphia-chromosome-negative e acute lymphoblastic leukaemia acute lymphoblastic leukaemia T echnology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta450 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>